Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Tests LT3001 for acute ischemic stroke in adults

Tests the drug LT3001 against a placebo in adults with acute ischemic stroke.

Plain-language title generated from the registry record
Registry title: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Key facts

Where
Baotou, Beijing, Changchun, Chaoyang, Daqing, Guangzhou, Hangzhou, Hengshui, Huai'an, Liaocheng, Linfen, Luoyang, Mianyang, Nanyang, Pingxiang, Shanghai, Suzhou, Taizhou, Wuhan, Xi’an, Xianyang, Xuzhou, and Zhanjiang, ChinaSee the 28 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 80 with an acute ischemic stroke who can receive the study drug within 24 hours of stroke onset.

Age
18 to 80 years
Sex
All sexes
Disease stage
Acute ischemic stroke causing neurological impairment, with an NIHSS score from 4 to 25 points at randomization; the drug must be given within 24 hours of stroke onset.
Earlier treatment
People who received or plan to receive endovascular treatment or intravenous thrombolytic therapy for this stroke cannot join.

Main reasons for not taking part

  • Endovascular treatment or intravenous thrombolytic therapy for this stroke
  • Brain bleeding disease, brain tumor or massive infarction on imaging
  • Blood pressure above 180/100 mmHg after treatment
  • Pregnant or breastfeeding women
  • Serious liver or kidney problems

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Source: NCT05686642, who can take part

Where in China

  • Inner Mongolia Baogang HospitalBaotou, ChinaContact: Dong WangTaking people
  • The First Affiliated Hospital of Baotou Medical CollegeBaotou, ChinaContact: Bo LiuTaking people
  • Beijing Luhe Hospital, Capital Medical UniversityBeijing, ChinaContact: Yanling WangTaking people
  • Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaContact: Yongjun WangTaking people
  • Beijing Tsinghua Changgung HospitalBeijing, ChinaContact: Jian WuTaking people
  • The First Bethune Hospital of Jilin UniversityChangchun, ChinaContact: Yi YangTaking people
  • Beipiao Central HospitalChaoyang, ChinaContact: Yutong MaTaking people
  • Daqing Oilfield General HospitalDaqing, ChinaContact: Jianghua LiuTaking people
  • The First Affiliated Hospital of Jinan UniversityGuangzhou, ChinaContact: An'ding XuTaking people
  • Zhejiang HospitalHangzhou, ChinaContact: Yaguo LiTaking people
  • Harrison International Peace HospitalHengshui, ChinaContact: Yan WeiTaking people
  • Huai'an Second People's HospitalHuai'an, ChinaContact: Liandong ZhaoTaking people
  • Liaocheng People's HospitalLiaocheng, ChinaContact: Cunju GuoTaking people
  • Linfen Central HospitalLinfen, ChinaContact: Hongguo DaiTaking people
  • Linfen People's HospitalLinfen, ChinaContact: Junfang HaoTaking people
  • Luoyang Third People's HospitalLuoyang, ChinaContact: Bing SunTaking people
  • The Third Hospital of MianyangMianyang, ChinaContact: Diwen ZhangTaking people
  • Nanshi Hospital of NanyangNanyang, ChinaContact: Bin LiuTaking people
  • Pingxiang People's HospitalPingxiang, ChinaContact: Fei YiTaking people
  • Shanghai Pudong HospitalShanghai, ChinaContact: Shuangxing HouTaking people
  • The Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: Chunfeng LiuTaking people
  • Taizhou First People's HospitalTaizhou, ChinaContact: Zhimin WangTaking people
  • Taizhou Municipal HospitalTaizhou, ChinaContact: Hao XuTaking people
  • Zhongnan Hospital of Wuhan UniversityWuhan, ChinaContact: Yumin LiuTaking people
  • Xi'an Gaoxin HospitalXi’an, ChinaContact: Yi JiaTaking people
  • Yan'an University Xianyang HospitalXianyang, ChinaContact: Lei LeiTaking people
  • The affiliated hospital of xuzhou medical universityXuzhou, ChinaContact: Deqin GengTaking people
  • Central people' s hospital of zhanjiangZhanjiang, ChinaContact: Hui MaiTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Shanghai Pharmaceuticals Holding Co., Ltd
Trial code
NCT05686642
Record updated
30 April 2026
Original description
This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic strokeRead full original descriptionShow less

A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS)

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

Inclusion: Subjects aged between 18 and 80 years at screening; Clinical diagnosis of acute ischemic stroke that causes evaluable neurological impairment; 3.4 points ≤ NIHSS score ≤ 25 points at randomization; 4.Subjects who are able to receive the investigational drug within 24 hours after the onset of stroke; 5.Female subjects of childbearing potential or male subjects whose sexual partner are women of childbearing potential have no pregnancy plan and voluntarily take effective contraceptive measures during the study period and for 3 months after the last dose; 6.All subjects sign the informed consent form by themselves or their guardians after receiving complete study information.

Exclusion: Subjects have received or plan to receive endovascular treatment and/or intravenous thrombolytic therapy recommended by Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018 during this onset period; Subjects who have used or are using protocol-prohibited medications after the onset; Patients who are unable to cooperate due to epileptic seizure at the onset of stroke or other concomitant mental disorders or are unwilling to cooperate; Systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg after active antihypertensive therapy; Subjects who underwent any major surgery before screening; Subjects who have participated in another investigational study and used investigational product before screening; Subjects with pre-stroke disability; Subjects with intracranial hemorrhagic diseases, tumor in brain parenchyma, arteriovenous malformation, aortic arch dissection, other central nervous system lesions that may increase the risk of hemorrhage, or imaging evidence for arterial aneurysm requiring treatment; Acute hemorrhage tendency; Active visceral hemorrhage; Subjects with a history of serious hypersensitivity; Subjects who experienced AIS, ICH, acute myocardial infarction or serious head trauma before screening; Subjects with a history of active digestive ulcer before screening; Subjects who experienced hemorrhagic disease before screening; Serious hepatic impairment or serious renal insufficiency; Other conditions unsuitable for participation in this study determined by the Investigator; Blood glucose level < 50 mg/dL or > 400 mg/dL; Presence of disturbances of consciousness at screening and NIHSS 1a ≥ 2 points; Neurological signs have improved rapidly and spontaneously at screening; Massive infarction on imaging; Lactating or pregnant subjects, or women of childbearing potential with positive pregnancy test results; International normalized ratio > 1.7 or prothrombin time > 15 s; Subjects who underwent arterial puncture at the site not easy for hemostasis by compression before screening.

ClinicalTrials.gov NCT05686642